Afectiuni tratate Reducerea stresului oxidativ Detoxifierea endogena Tratament adjuvant in afectiuni oculare (degenerescenta maculara, cataracta) Tratament adjuvant in afectiuni neurodegenerative (boala Parkinson, maladia Alzheimer, SLA, scleroza multipla, simptome in autism) Protectie cardiovasculara (scade nivelul de colesterol, previne peroxidarea lipidica, antiaterogen) Protectie pulmonara (astm, bronsite cronice, emfizem, fibroza chistica Protectie sistem digestiv (boala Crohn, ulcere provocate de infectia cu Helicobacter pylori, gastrita, colita) Protectie impotriva leziunilor si emboliilor cerebrale Reducerea infertilitatii masculine Reducerea efectelor negative ale chimio si radioterapiei Tratament adjuvant in psoriazis Protectie impotriva radiatiilor ultraviolete
Currently, the most popular GLP-1s available in the UK are Mounjaro and Wegovy
Oral GLP-1s (Lillys paltusotine-orforglipron, etc.) are expected in late 2025/2026, and might be covered differently (some plans treat orals less restrictively than injectables)
KPV targets NF-kB, a protein complex that acts as a master switch for inflammatory gene expression
doi: 10.1126/science.adt0548 27
While reducing antibodies does not always mean a "cure", it can sometimes correlate with a feeling of improved well-being and may, in some cases, slow the progression of the disease
)
)
